January 12th, 2015
High Rate of Inappropriate Use of Aspirin for Primary Prevention
Larry Husten, PHD
More than a third of U.S. adults — more than 50 million people — now take aspirin for the primary and secondary prevention of cardiovascular disease. Although it was once broadly recommended, aspirin for the primary prevention of cardiovascular disease is now only indicated in people who have a moderate-to-high 10-year risk. Now a new report published in […]
January 9th, 2015
Top 10 CardioExchange Posts from 2014
Harlan M. Krumholz, MD, SM and John Ryan, MD
The most popular stories from 2014.
January 9th, 2015
FDA Approves New Oral Anticoagulant from Daiichi Sankyo
Larry Husten, PHD
And then there were four. Late Thursday the FDA announced that it had approved edoxaban, the new oral anticoagulant manufactured by Daiichi Sankyo. The drug will be marketed under the brand name of Savaysa and joins three other new drugs in the large and important new oral anticoagulant marketplace: dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). All four drugs […]
January 5th, 2015
Selections from Richard Lehman’s Literature Review: January 5th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include metformin in patients with type 2 diabetes and kidney disease, mortality and treatment patterns among patients hospitalized with acute CV conditions during national cardiology meetings, and more.
January 5th, 2015
Screening Heart-Failure Patients for Cognitive Impairment at Discharge
Eiran Gorodeski, MD, MPH
Eiran Gorodeski discusses his research group’s study of cognitive-impairment screening for patients who are hospitalized for heart failure.
January 5th, 2015
FDA Approves New Drug-Coated Balloon to Open Blocked Leg Arteries
Larry Husten, PHD
Medtronic said today that it had received approval from the FDA to market its IN.PACT Admiral drug-coated balloon (DCB) to treat peripheral artery disease (PAD) in the superficial femoral and popliteal arteries. The device is the second DCB to gain FDA approval. Last October the FDA approved CR Bard’s Lutonix DCB for a similar indication. The new DCB uses the anti-proliferative drug […]
January 5th, 2015
Healthy Habits of Young Women Lead to Long-Term Health Benefits
Larry Husten, PHD
It may seem obvious, but a new study shows that young women with healthy habits are less likely as they age to get coronary heart disease or go on to develop cardiovascular risk factors like high blood pressure, high cholesterol, or diabetes. Andrea Chomistek and colleagues analyzed data from more than 88,000 women participating in […]